Afimkibart is an investigational TL1A inhibitor, a therapeutic class designed to modulate inflammation by targeting the TL1A pathway. This page compares Afimkibart to other agents, including Etrasimod (Velsipity) and Vedolizumab (Entyvio), which represent different therapeutic approaches for inflammatory conditions. These treatments vary in their mechanisms of action and routes of administration.
Afimkibart Alternatives: How It Compares to Other TL1A Inhibitors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/3 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
Vedolizumab (Entyvio) was approved in 2014 and Etrasimod (Velsipity) in 2023. Afimkibart is not yet approved, and there are no other drugs currently in Phase 3 development.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Afimkibart | TL1A inhibitor | — | — | Pipeline | — | — |
| Vedolizumab (Entyvio) | alpha-4 beta-7 integrin inhibitor | ulcerative colitis, Crohn's disease | 300 mg IV at weeks 0, 2, and 6, then 300 mg IV every 8 weeks; or 108 mg subcutaneously every 2 weeks for maintenance. | 2014 | 41.8% @ week 52 | $45k |
| Etrasimod (Velsipity) | S1P receptor modulator | ulcerative colitis | 2 mg orally once daily | 2023 | 32.1% @ week 52 | $75k |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Clinical remission; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for ulcerative colitis specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Afimkibart vs Etrasimod (Velsipity)
No head-to-head Phase-3 trial directly compares Afimkibart with Etrasimod.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Afimkibart vs Vedolizumab (Entyvio)
No head-to-head Phase-3 trial directly compares Afimkibart with Vedolizumab.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Choosing between Afimkibart and its alternatives
When considering Afimkibart, its mechanism as a TL1A inhibitor represents a novel therapeutic approach. This distinct target may offer an important option for patients who have not responded to therapies with other mechanisms of action.
In contrast, established therapies like Etrasimod (Velsipity) and Vedolizumab (Entyvio) offer different mechanisms and known efficacy profiles. Etrasimod, an S1P receptor modulator, is administered as a 2 mg oral dose once daily, achieving clinical remission in 32.1% of patients at week 52. Vedolizumab, an alpha-4 beta-7 integrin inhibitor, demonstrated clinical remission in 41.8% of patients at week 52, with dosing options including intravenous administration at weeks 0, 2, and 6, then every 8 weeks, or 108 mg subcutaneously every 2 weeks for maintenance. These agents may be preferred based on their longer clinical experience, specific mechanistic considerations, or established efficacy for particular patient profiles.
This information is for educational purposes only and does not constitute medical advice; clinical decisions should always be made by a qualified prescriber in consultation with their patient.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
afimkibartafimkibart alternativesalternativescomparisonulcerative colitisafimkibart-tl1a-ulcerative-colitisafimkibart vs etrasimodafimkibart vs vedolizumab